Gene Therapies in Ophthalmology Market Competitive Landscape Report 2026: Comprehensive Insights About 55+ Companies and 125+ Drugs by Product Type, Stage, Route of Administration, and Mol...
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
The sector benefits from the eye's unique characteristics, making it an ideal target. Collaborations, acquisitions, and innovative therapies drive growth and enhance patient outcomes. Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Gene Therapies in Ophthalmology - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering. This "Gene Therapies In Ophthalmology- Competitive landscape, 2026," report provides comprehensive insights about 55+ companies and 125+ drugs in Gene Therapies In Ophthalmology Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Questions How many companies are developing Gene Therapies in Ophthalmology drugs? How many Gene Therapies in Ophthalmology drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXPR Newswire
- Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor HarmGlobeNewswire
- Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmPR Newswire
RGNX
Earnings
- 3/5/26 - Miss
RGNX
Sec Filings
- 4/14/26 - Form ARS
- 4/14/26 - Form DEFA14A
- 4/14/26 - Form DEF
- RGNX's page on the SEC website